Agilent Sponsors International Food Analysis Symposium in Prague Agilent to demonstrate the strength and acceleration of its technological innovations in food analytics at RAFA 2017 SANTA CLARA, Calif., Nov. 2, 2017 Agilent Technologies Inc. (NYSE: A) today announced that it will showcase some of its most recent technological advances at the 8th International Symposium on... Read more
New CRISPR-based Transcriptional Activation and Interference (a/i) Libraries SANTA CLARA, Calif., October 17, 2017 Agilent Technologies Inc. (NYSE: A) today announced the first expansion of the SureGuide pooled CRISPR libraries for functional genomics, offering pooled libraries for CRISPR activation and interference (CRISPR a/i). The announcement was made at the at the American Society for Human... Read more
Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease Research New CRISPR-based Transcriptional Activation and Interference (a/i) Libraries SANTA CLARA, Calif., October 17, 2017 Agilent Technologies Inc. (NYSE: A) today announced the first expansion of the SureGuide pooled CRISPR libraries for functional genomics, offering pooled libraries for CRISPR activation and interference (CRISPR a/i). The... Read more
Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SANTA CLARA, Calif., September 22, 2017 Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by U.S. Food and Drug... Read more
Strategic Sponsorship Will Provide Innovative Technology and Nurture Promising Biotechnology Startup SANTA CLARA, Calif., September 19, 2017 Agilent Technologies Inc. (NYSE: A) has announced a platinum sponsorship agreement with LabCentral, a biotech innovation hub based in Cambridge, Massachusetts. LabCentral is an independent, shared laboratory space designed as a launchpad for high-potential life sciences and biotech... Read more
Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications SANTA CLARA, Calif., September 19, 2017 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma (UC) and of squamous cell carcinoma... Read more
Assay Detects Genetic Anomalies and Helps Move Inquiries from Cause to Care Faster SANTA CLARA, Calif., September 13, 2017 Agilent Technologies Inc. (NYSE: A) has announced that it has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization (CGH) assay for diagnostic... Read more
Awarded to the Agilent IQFISH Panel for Lung Cancer SANTA CLARA, Calif., September 5, 2017 Agilent Technologies Inc. (NYSE: A) has received a 2017 Scientists’ Choice Award for Best New Clinical Laboratory Product: the IQFISH Panel for Lung Cancer. The IQFISH panel for lung cancer makes it easier for pathology labs to integrate fast, high-quality... Read more
SANTA CLARA, Calif., August 24, 2017 Agilent Technologies Inc. (NYSE: A) announced the following webcast for the investment community: Morgan Stanley Global Healthcare Conference Grand Hyatt Hotel, New York City Tuesday, September 12, at 2:05 p.m. EDT Mark Doak, President, Agilent’s CrossLab Group A link to the webcast will be available at www.investor.agilent.com. About Agilent... Read more
Files civil lawsuit against Shanghai Echrom Electronic Technology Co., including former Agilent employees August 22, 2017 08:00 PM Pacific Daylight Time BEIJING–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE:A) has filed a civil lawsuit against Shanghai Echrom Electronic Technology Co., Ltd., and several former employees of Agilent, alleging infringement of trade secrets and petitioning the court to stop... Read more